Key terms
About ATXS
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ATXS news
Yesterday
6:20am ET
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)
Yesterday
6:05am ET
Astria Therapeutics price target lowered to $16 from $18 at H.C. Wainwright
Apr 09
8:22am ET
Astria Therapeutics Expands Board, Appoints New Director
Mar 26
8:15am ET
Wedbush Remains a Buy on Astria Therapeutics (ATXS)
Mar 26
6:45am ET
Buy Recommendation for Astria Therapeutics Backed by Promising ALPHA-STAR Trial Results
Mar 25
5:17pm ET
Spyre Therapeutics price target raised to $54 from $36 at Stifel
Mar 25
2:05pm ET
Buy Rating Affirmed for Astria Therapeutics on Promising STAR-0215 Data and Market Potential
Mar 25
12:50pm ET
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Astria Therapeutics (ATXS)
Mar 25
7:35am ET
Astria: ‘Positive’ initial proof-of-concept results from STAR-0215 for HAE trial
Mar 14
6:26am ET
Astria Therapeutics: A Strong Buy on Promising ALPHA-STAR Trial and Potential Market Edge with STAR-0215
Mar 11
8:25am ET
Buy Rating on Astria Therapeutics: Anticipating Market Growth with STAR-0215’s Advancements in HAE Treatment
Mar 06
1:01am ET
Astria Therapeutics, Inc. Is Worried About This – Should You Be Worried Too?
Mar 05
7:31am ET
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Astria Therapeutics (ATXS)
Mar 05
6:45am ET
Astria Therapeutics: A Strong Buy on Groundbreaking HAE Therapy and Robust Financial Health
Mar 05
6:20am ET
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Astria Therapeutics (ATXS)
Mar 04
4:13pm ET
Astria Therapeutics reports Q4 EPS (86c), consensus (78c)
Feb 21
7:42am ET
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Medtronic (MDT) and Astria Therapeutics (ATXS)
Feb 21
7:41am ET
Oppenheimer Sticks to Its Buy Rating for Astria Therapeutics (ATXS)
Feb 06
8:12am ET
Buy Rating on Astria Therapeutics Supported by STAR-0215’s Promising Market Potential and Favorable Trial Results
Feb 06
8:10am ET
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Astria Therapeutics (ATXS) and Inspire Medical Systems (INSP)
Jan 30
9:16am ET
Astria Therapeutics 10.34M share Secondary priced at $12.09
No recent press releases are available for ATXS
ATXS Financials
Key terms
Ad Feedback
ATXS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ATXS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
